Prostate-specific membrane antigen (PSMA) PET has become a standard of care for prostate cancer (PCa) imaging, as demonstrated by its inclusion in the most recent guidelines from the National Comprehensive Cancer Network (1). Here, FOLH1 is linked to prostate carcinoma.